{"id":612529,"date":"2022-08-18T19:06:01","date_gmt":"2022-08-18T19:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=612529"},"modified":"2022-08-18T19:06:01","modified_gmt":"2022-08-18T19:06:01","slug":"nonradiographic-axial-spondyloarthritis-nraxspa-market-to-register-immense-growth-by-2032-asserts-delveinsight-key-companies-ucb-galapagos-novartis-sun-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonradiographic-axial-spondyloarthritis-nraxspa-market-to-register-immense-growth-by-2032-asserts-delveinsight-key-companies-ucb-galapagos-novartis-sun-pharma-and-others_612529.html","title":{"rendered":"Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market to Register Immense Growth by 2032 – Asserts DelveInsight | Key Companies – UCB, Galapagos, Novartis, Sun Pharma, and Others"},"content":{"rendered":"
\n
\"Non-Radiographic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, increasing prevalent population of nr-axSpA, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.<\/div>\n

DelveInsight’s “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Radiographic Axial Spondyloarthritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Non-Radiographic Axial Spondyloarthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Non-Radiographic<\/p>\n

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): An Overview<\/strong><\/p>\n

Axial spondyloarthritis (axSpA) is an umbrella term for inflammatory arthritis types that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS).<\/p>\n

“Non-radiographic” means that the disease causes symptoms, but damage to the joints is not visible on X-ray. When changes to the vertebrae (the bones of the spine) or SI joints do not show any X-ray changes, it is known as nr-axSpA. Once the joints are affected by an X-ray, a person can be diagnosed with AS.<\/em><\/p>\n

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Key Facts<\/strong><\/p>\n